Literature DB >> 25504618

Flexible, scalable, and efficient targeted resequencing on a benchtop sequencer for variant detection in clinical practice.

Kim De Leeneer1, Jan Hellemans, Wouter Steyaert, Steve Lefever, Inge Vereecke, Eveline Debals, Brecht Crombez, Machteld Baetens, Mattias Van Heetvelde, Frauke Coppieters, Jo Vandesompele, Annelies De Jaegher, Elfride De Baere, Paul Coucke, Kathleen Claes.   

Abstract

The release of benchtop next-generation sequencing (NGS) instruments has paved the way to implement the technology in clinical setting. The need for flexible, qualitative, and cost-efficient workflows is high. We used singleplex-PCR for highly efficient target enrichment, allowing us to reach the quality standards set in Sanger sequencing-based diagnostics. For the library preparation, a modified NexteraXT protocol was used, followed by sequencing on a MiSeq instrument. With an innovative pooling strategy, high flexibility, scalability, and cost-efficiency were obtained, independent of the availability of commercial kits. The approach was validated for ∼250 genes associated with monogenic disorders. An overall sensitivity (>99%) similar to Sanger sequencing was observed in combination with a positive predictive value of >98%. The distribution of coverage was highly uniform, guaranteeing a minimal number of gaps to be filled with alternative methods. ISO15189-accreditation was obtained for the workflow. A major asset of the singleplex PCR-based enrichment is that new targets can be easily implemented. Diagnostic laboratories have validated assays available ensuring that the proposed workflow can easily be adopted. Although our platform was optimized for constitutional variant detection of monogenic disease genes, it is now also used as a model for somatic mutation detection in acquired diseases.
© 2014 WILEY PERIODICALS, INC.

Keywords:  ISO15189 accreditation; NGS; clinical implementation; targeted resequencing; uniform target enrichment

Mesh:

Year:  2015        PMID: 25504618     DOI: 10.1002/humu.22739

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  25 in total

1.  Dealing with Pseudogenes in Molecular Diagnostics in the Next Generation Sequencing Era.

Authors:  Kathleen B M Claes; Toon Rosseel; Kim De Leeneer
Journal:  Methods Mol Biol       Date:  2021

2.  A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma.

Authors:  S Dvorakova; V Sykorova; E Vaclavikova; P Sykorova; P Vlcek; D Kodetova; P Lastuvka; J Betka; M Mokrejs; J Vcelak; B Bendlova
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

3.  Homozygous stop mutation in AHR causes autosomal recessive foveal hypoplasia and infantile nystagmus.

Authors:  Anja K Mayer; Muhammad Mahajnah; Mervyn G Thomas; Yuval Cohen; Adib Habib; Martin Schulze; Gail D E Maconachie; Basamat AlMoallem; Elfride De Baere; Birgit Lorenz; Elias I Traboulsi; Susanne Kohl; Abdussalam Azem; Peter Bauer; Irene Gottlob; Rajech Sharkia; Bernd Wissinger
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

4.  Human germline nuclear transfer to overcome mitochondrial disease and failed fertilization after ICSI.

Authors:  Maoxing Tang; Annekatrien Boel; Noemi Castelluccio; Arantxa Cardona Barberán; Antonia Christodoulaki; Bieke Bekaert; Mina Popovic; Frauke Vanden Meerschaut; Petra De Sutter; Björn Menten; Sofie Symoens; Arnaud V Vanlander; Dominic Stoop; Paul J Coucke; Björn Heindryckx
Journal:  J Assist Reprod Genet       Date:  2022-01-22       Impact factor: 3.412

5.  Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.

Authors:  Frauke Coppieters; Giulia Ascari; Katharina Dannhausen; Konstantinos Nikopoulos; Frank Peelman; Marcus Karlstetter; Mingchu Xu; Cécile Brachet; Isabelle Meunier; Miltiadis K Tsilimbaris; Chrysanthi Tsika; Styliani V Blazaki; Sarah Vergult; Pietro Farinelli; Thalia Van Laethem; Miriam Bauwens; Marieke De Bruyne; Rui Chen; Thomas Langmann; Ruifang Sui; Françoise Meire; Carlo Rivolta; Christian P Hamel; Bart P Leroy; Elfride De Baere
Journal:  Am J Hum Genet       Date:  2016-08-04       Impact factor: 11.025

6.  A Novel Non-Coding Variant in DCLRE1C Results in Deregulated Splicing and Induces SCID Through the Generation of a Truncated ARTEMIS Protein That Fails to Support V(D)J Recombination and DNA Damage Repair.

Authors:  Steven Strubbe; Marieke De Bruyne; Ulrich Pannicke; Elien Beyls; Bart Vandekerckhove; Georges Leclercq; Elfride De Baere; Victoria Bordon; Anne Vral; Klaus Schwarz; Filomeen Haerynck; Tom Taghon
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

7.  Profiling of conserved non-coding elements upstream of SHOX and functional characterisation of the SHOX cis-regulatory landscape.

Authors:  Hannah Verdin; Ana Fernández-Miñán; Sara Benito-Sanz; Sandra Janssens; Bert Callewaert; Kathleen De Waele; Jean De Schepper; Inge François; Björn Menten; Karen E Heath; José Luis Gómez-Skarmeta; Elfride De Baere
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

8.  Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.

Authors:  Annelot Baert; Julie Depuydt; Tom Van Maerken; Bruce Poppe; Fransiska Malfait; Katrien Storm; Jenneke van den Ende; Tim Van Damme; Sylvia De Nobele; Gianpaolo Perletti; Kim De Leeneer; Kathleen B M Claes; Anne Vral
Journal:  Breast Cancer Res       Date:  2016-05-17       Impact factor: 6.466

9.  Targeted resequencing and variant validation using pxlence PCR assays.

Authors:  Frauke Coppieters; Kimberly Verniers; Kim De Leeneer; Jo Vandesompele; Steve Lefever
Journal:  Biomol Detect Quantif       Date:  2015-10-09

10.  BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.

Authors:  F Z Francies; T Wainstein; K De Leeneer; A Cairns; M Murdoch; S Nietz; H Cubasch; B Poppe; T Van Maerken; B Crombez; I Coene; R Kerr; J P Slabbert; A Vral; A Krause; A Baeyens; K B M Claes
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.